Abstract: A prosthetic venous valve having a conical shaped base valve member and a biomaterial delivery construct. The base valve member includes a plurality of fluid flow modulating means that open and allow antegrade blood to be transmitted out of the valve member when the valve member receives antegrade blood therein, and close and prevent retrograde blood from flowing into the valve member. The biomaterial delivery construct is adapted to receive and position the base valve member therein, and be disposed proximate a luminal wall of a venous vessel.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include a plurality of particulate structures. The particulate structures further include an acellular ECM core and an outer layer or coating comprising poly(glycerol sebacate) (PGS) and everolimus. When the particulate structures are delivered to the damaged cardiovascular tissue the outer layer is adapted to induce a first level of remodeling and suppress hyperplasia, and the acellular ECM is adapted to induce a second level of remodeling.

Abstract: An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include particulate structures that are formed from an ECM/ECM-mimicking composition. The ECM/ECM-mimicking composition consists of a mixture of particulate structures including particulate structures formed from acellular ECM derived from a mammalian tissue source and particulate structures formed from poly(glycerol sebacate) (PGS) and everolimus.

Abstract: A conical shaped venous valve structure formed from collagenous mammalian tissue.

Abstract: A prosthetic valve comprising a conical shaped sheet structure and a support structure, the sheet structure having a closed distal end and a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, whereby the ribbon members form a plurality of fluid flow modulating regions that close when fluid flow through the valve exhibits a negative flow pressure and open when fluid flow through the valve exhibits a positive flow pressure, the support structure having at least one elongated cardiovascular structure engagement member that is associated with one of the ribbon members and adapted to engage a cardiovascular structure.

Abstract: Prosthetic valves that include conical shaped base valve members having an annular engagement end, a closed distal end region that restricts fluid flow therethrough, and a plurality of elongated ribbon members, which transition from an open fluid flow configuration to a closed fluid flow configuration in response to expansion and contraction of the base valve member, and a support structure that is configured and adapted to exert retaining forces on the annular engagement ends of the base valve members, whereby the support structure (i) conforms to the shape of the annular engagement ends of the base valve members, (ii) securely positions the annular engagement ends of the base valve members adjacent to and, thereby, in contact with a valve annulus, whereby the annular engagement ends of the base valve members conform to the shape of the valve annulus, and (iii) the annular engagement ends of the base valve members adapt to at least one fluctuation in the configuration and/or dimension of the valve annulus, w

Abstract: Prosthetic heart valves having a conical shaped base valve structure formed from collagenous mammalian tissue. The base valve structure includes a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, wherein the elongated ribbon members are positioned adjacent each other and form a plurality of fluid flow modulating regions that open when fluid into and through the base valve structure exhibits a positive pressure relative to the exterior pressure, i.e., a positive pressure differential, wherein the fluid is allowed to be transmitted out of the base valve structure, and transition to a closed configuration when the pressure differential between the interior valve pressure and exterior pressure reduces, wherein the fluid is restricted from flowing out of the base valve structure.

Abstract: A prosthetic valve comprising a tubular shaped sheet member comprising an extracellular matrix (ECM) composition, the sheet member having a plurality of ribbons having proximal and distal ends, the distal ends of the ribbons projecting from the sheet member proximal end.

Abstract: A biocompatible and biodegradable construct having a base expandable member and an integral, internal support structure. The support structure is preferably formed from poly(glycerol sebacate) (PGS) or a magnesium alloy. The base member is preferably formed from acellular extracellular matrix (ECM) derived from small intestine submucosa (SIS) tissue that exhibits a flexible, porous, sponge-like structure adapted to expand upon absorption of a bodily fluid, wherein the construct seals a perivalvular leak when disposed proximate thereto.

Abstract: A prosthetic valve comprising a conical shaped ribbon structure comprising an extracellular matrix (ECM) composition. The ribbon structure comprises a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, wherein the ribbon members are positioned adjacent each other and form a plurality of fluid flow modulating regions that open when fluid flow through the valve exhibits a negative flow pressure and open when fluid flow through the valve exhibits a positive flow pressure.

Abstract: A percutaneous transseptal surgical implantation method for replacing a defective atrioventricular (AV) valve with a conical shaped prosthetic valve formed from extracellular matrix (ECM) tissue. When the method is employed to replace a native mitral valve, the method positions the prosthetic tissue valve in the mitral valve region, whereby the valve does not obstruct the outflow tract of the aortic valve and prevents the leaflets of the aortic valve from coapting.

Abstract: A percutaneous transseptal surgical implantation method for replacing a defective atrioventricular (AV) valve with a conical shaped prosthetic valve formed from a polymeric composition. When the method is employed to replace a native mitral valve, the method positions the prosthetic valve in the mitral valve region, whereby the valve does not obstruct the outflow tract of the aortic valve and prevents the leaflets of the aortic valve from coapting.

Abstract: Methods for treating cardiovascular disorders that include administration of an ECM based composition to damaged cardiovascular tissue in conjunction with a treatment remedy, such as transmyocardial revascularization (TMR), which induces enhanced bioremodeling of the damaged cardiovascular tissue and regeneration of new cardiovascular tissue and associated structures with site-specific structural and functional properties.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include particulate structures that are formed from PGS, cerivastatin and everolimus. The particulate structures are configured to modulate inflammation of damaged cardiovascular tissue in vivo by increasing expression of Kruppel like factor 2 (KLF-2), whereby localized expression of monocyte chemoattractant protein 1 (MCP-1) and C-C chemokine receptor type 2 (CCR2) is inhibited at transcriptional and translational levels as a function of the KLF-2 modulation.

Abstract: Methods for treating damaged cardiac tissue by delivering biological formulations proximate the pericardial space of a mammalian heart that (i) enhance and supplement the properties provided by the GATA6+ macrophages in the serous fluid and/or (ii) restore, enhance and supplement the properties provided by the GATA6+ macrophages when the pericardial space is breached and the serous fluid is expelled.

Abstract: Methods for treating cardiovascular disorders that include administration of an ECM based composition to damaged cardiovascular tissue in conjunction with a treatment remedy, such as ventricular assistance and transmyocardial revascularization (TMR), which induces enhanced bioremodeling of the damaged cardiovascular tissue and regeneration of new cardiovascular tissue and associated structures with site-specific structural and functional properties.

Abstract: Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that are formed from acellular extracellular matrix (ECM). The cardiovascular prostheses comprise an ECM-mimicking composition comprising poly(glycerol sebacate) (PGS) and a cytokine.

Abstract: A percutaneous transseptal surgical implantation method for replacing a defective atrioventricular (AV) valve with a conical shaped prosthetic valve formed from extracellular matrix (ECM) tissue. When the method is employed to replace a native mitral valve, the method positions the prosthetic tissue valve in the mitral valve region, whereby the valve does not obstruct the outflow tract of the aortic valve and prevents the leaflets of the aortic valve from coapting.

Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.